What makes ozempic's structure stand out?

Why Ozempic’s (semaglutide) structure is so distinctive

| Feature | What it is | Why it matters |
|---------|-----------|----------------|
| Base scaffold – GLP‑1(7‑36) amide | A 30‑residue peptide that mimics the natural incretin hormone GLP‑1, with the C‑terminus amidated for stability. | Keeps the receptor‑binding profile of native GLP‑1. |
| A single amino‑acid substitution (A8 → S‑2‑aminoisobutyric acid, Aib) | A non‑natural residue at position 8 (normally alanine). | Blocks rapid cleavage by DPP‑4, the enzyme that degrades native GLP‑1, giving the peptide a much longer “first‑pass” half‑life. |
| C‑terminal lysine (Lys‑34) conjugated with a fatty acid tail | A C20 fatty acid (20‑carbon chain) is linked to Lys‑34 via a short, flexible spacer (glutamic‑acid‑based linker). | The long, hydrophobic tail binds strongly to serum albumin. Because albumin circulates for ~19 days, the drug “hides” in the plasma and is released slowly, providing a week‑long effect with only one injection. |
| No disulfide bonds | The peptide is a linear, single‑chain molecule (unlike some other peptide drugs that form loops). | Simpler manufacturing and reduces potential for aggregation. |
| Molecular weight ≈ 4.9 kDa | Small enough to be produced by peptide synthesis yet large enough to resist renal clearance. | Balances stability with ease of synthesis. |

Putting it together

Ozempic’s design turns a normally short‑lived hormone (GLP‑1) into a long‑acting drug by combining